Tectonic Therapeutic, Inc. (TECX): Total Liabilities
$9.71M
As of 2025-12-31
$13.19M
As of 2026-06-30
-30.2%
3-year compound annual growth
-10.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.71M | -20.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $12.13M | -72.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $43.41M | +51.9% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $28.58M | -16.8% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $34.36M | +103.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $16.89M | +16.5% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $14.50M | +28.4% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $11.29M | +208.9% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $3.66M | n/a | 2019-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $9.71M | -20.0% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $197.33M | -66.0% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $22.02M | -26.8% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $35.34M | -43.0% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
Compare TECX, CHRS, LXEO, VYGR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗